Short Wave Could Psychedelics Become Tripless?
23 snips
Apr 9, 2025 
Rachel Carlson, a dedicated producer and reporter on psychedelic science, dives into the fascinating world of non-hallucinogenic alternatives to traditional psychedelics. She discusses groundbreaking research on modifying these compounds to retain their therapeutic benefits while eliminating hallucinatory experiences. The conversation explores innovative treatments, such as 'psychoplastogens' and the promising drug DLX1 aimed at tackling conditions like depression. Carlson also highlights the ongoing debates on the necessity of trips in psychedelic therapy, offering a glimpse into the future of mental health treatment.
AI Snips
Chapters
Transcript
Episode notes
Accessibility of Psychedelic Therapy
- Some researchers acknowledge the importance of non-drug factors in psychedelic therapy.
- However, they also recognize that psychedelics aren't suitable for everyone, like those with bipolar disorder or schizophrenia.
Tripless Psychedelics
- David Olson, a chemical neuroscientist, is developing psychedelic-inspired drugs without the hallucinogenic effects.
- His company, Delix Therapeutics, modifies the structures of existing psychedelics like ketamine and LSD to create these new compounds.
History of Tripless Psychedelics
- The concept of non-hallucinogenic psychedelics isn't new; even Albert Hofmann, the creator of LSD, explored similar derivatives.
- Some scientists, however, believe the hallucinogenic experience is crucial for therapeutic effects.